The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev
• 1 Sep 2020
Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of JAK1 and JAK2 inhibitors in patients undergoing allogeneic stem-cell transplantation (allo-HSCT) for BCR-ABL negative myeloproliferative neoplasms (MPNs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
